CONDOR

EQS-News: Mynaric Secures Additional Contract with U.S. Customer for its CONDOR Mk3 Terminals

Retrieved on: 
Tuesday, November 7, 2023
CONDOR, FRA, Mynaric

Customer for its CONDOR Mk3 Terminals

Key Points: 
  • Customer for its CONDOR Mk3 Terminals
    The issuer is solely responsible for the content of this announcement.
  • MUNICH, October 31, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced that it entered into an additional definitive agreement with a previously undisclosed U.S.-based customer for the delivery of CONDOR Mk3 optical communication terminals.
  • "We are delighted to announce that we have successfully secured another contract for our flagship product, CONDOR Mk3.
  • Wins such as this in an expanding market for laser communication products highlight our industry-leading position," said Mustafa Veziroglu, CEO of Mynaric.

EQS-News: Mynaric passes major product milestone of CONDOR Mk3, completing verification and interoperability tests

Retrieved on: 
Thursday, September 28, 2023
CONDOR, SDA, United States Naval Research Laboratory, Tranche, Space Development Agency, FRA, Acquisition, OCT, Printed circuit board, Mynaric

Mynaric passes major product milestone of CONDOR Mk3, completing verification and interoperability tests

Key Points: 
  • Mynaric passes major product milestone of CONDOR Mk3, completing verification and interoperability tests
    The issuer is solely responsible for the content of this announcement.
  • MUNICH, September 28, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced an important product milestone of its CONDOR Mk3 optical communications terminals.
  • Mynaric will supply the CONDOR Mk3 terminals to Northrop Grumman’s satellites for the Tranche 1 Transport and Tracking Layer programs .
  • Subsequent optical interoperability tests, conducted at the Naval Research Lab , successfully demonstrated the product’s capability to optically interconnect with terminals from other vendors.

EQS-News: Mynaric Announces Half-Year 2023 Results

Retrieved on: 
Saturday, September 16, 2023
CONDOR, Q&A, Central European Summer Time, History, FRA, Interest, Raytheon Technologies, EUR, CFO, Webcast, Rare-earth element, Cryptocurrency, Mynaric

MUNICH, September 14, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announces results for the half year ending June 30, 2023.

Key Points: 
  • MUNICH, September 14, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announces results for the half year ending June 30, 2023.
  • Mynaric is providing the following key performance indicators outlook for 2023:
    Mynaric has scheduled a webcast to discuss its half-year 2023 financial results to be held today, Thursday, September 14, 2023, at 12:00 p.m. Eastern Daylight Time (6:00 p.m. Central European Summer Time).
  • The conference call and webcast will include a presentation of these results along with a Q&A session with Mynaric executives including CEO, Mustafa Veziroglu, and CFO, Stefan Berndt-von Bülow.
  • Interested parties may listen to the webcast on the Investor Relations section of mynaric.com by pre-registering at the following registration link: Mynaric Half-Year 2023 Earnings Webcast Registration .

Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe

Retrieved on: 
Tuesday, July 25, 2023
Curium, Partnership, CONDOR, PSMA, Deep learning, Clinical trial, European Directive on Traditional Herbal Medicinal Products, Cancer, McDonnell Douglas F/A-18 Hornet, Intelligence, PYTHON, PET, Committee, Nuclear medicine, Data, Patient, Artificial intelligence, European Medicines Agency, Diagnosis, AI, Prostate cancer, Medical imaging, European

The agreement builds on the existing prostate cancer PSMA-targeted PET imaging collaboration between Curium and Lantheus with an exclusive licensing and development agreement for AI-powered quantitative analysis and standardized reporting of PSMA PET/CT image assessments.

Key Points: 
  • The agreement builds on the existing prostate cancer PSMA-targeted PET imaging collaboration between Curium and Lantheus with an exclusive licensing and development agreement for AI-powered quantitative analysis and standardized reporting of PSMA PET/CT image assessments.
  • Under the terms of the agreement, EXINI’s deep learning platform will be tailored to meet the specific needs of the European market.
  • With the expanding treatment options in prostate cancer, including PSMA RLT, there is increasing demand for efficient, standardized quantitative assessment of PSMA disease burden.
  • Our partnership with Curium expands the pool of patient data informing our AI algorithm and enables more widespread access to our software.”

Curium Announces Publication of [18F]DCFPyL Versus [18F]Fluoromethylcholine Results From European Phase III Study (PYTHON Trial)

Retrieved on: 
Friday, July 21, 2023
Curium, CONDOR, 18F, Prostate cancer, PSMA, Molecular imaging, European Directive on Traditional Herbal Medicinal Products, Cancer, PET, PYTHON, Google Images, Committee, Manuscript, Food and Drug Administration Amendments Act of 2007, MD, Patient, Master of Science, Chief Medical Officer (Ireland), PET/CT, European Medicines Agency, Phase, FDA, Recurrence, MD–PhD, European Journal, Food, European Journal of Nuclear Medicine and Molecular Imaging, Medical imaging, Nuclear medicine

PARIS, July 21, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the publication of the results of its European, multicenter, prospective cross-over clinical trial which compared [18F] piflufolastat ([18F]DCFPyL) versus [18F]fluoromethylcholine PET/CT in patients with first biochemical recurrence of prostate cancer.

Key Points: 
  • PARIS, July 21, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the publication of the results of its European, multicenter, prospective cross-over clinical trial which compared [18F] piflufolastat ([18F]DCFPyL) versus [18F]fluoromethylcholine PET/CT in patients with first biochemical recurrence of prostate cancer.
  • The results of the PYTHON trial were published online ahead of print in the European Journal of Nuclear Medicine and Molecular Imaging in June 2023.
  • The PYTHON Study (NCT04734184) was a Phase III, European, multicenter, prospective cross-over trial, to evaluate and compare the detection rates, impact on patient management and safety profiles of [18F]DCFPyL and [18F]fluoromethylcholine, in patients with first biochemical recurrence after initial definitive therapy with curative intent.
  • This study successfully met the primary endpoint.

EQS-News: Mynaric AG: Mynaric selected by Raytheon Technologies to supply optical communications terminals for SDA Tranche 1 Tracking Layer program

Retrieved on: 
Wednesday, June 21, 2023
Raytheon Intelligence & Space, Australian Space Agency, Communication, CONDOR, SDA, Northrop Grumman, U.S. Department of Defense Strategy for Operating in Cyberspace, ESA, Atmosphere, Telesat, Tranche, Space Development Agency, European Space Agency, Northrop, Grumman, FRA, App Store (iOS/iPadOS), Government, DARPA, Raytheon Intelligence, Information and Services, LOS, News, Security (finance), Communications satellite, Raytheon Technologies, Mynaric

LOS ANGELES, June 21, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced that it has been selected by Raytheon Technologies to supply optical communications terminals for the Space Development Agency (SDA) Tranche 1 Tracking Layer program.

Key Points: 
  • LOS ANGELES, June 21, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced that it has been selected by Raytheon Technologies to supply optical communications terminals for the Space Development Agency (SDA) Tranche 1 Tracking Layer program.
  • Each satellite will feature three optical communications terminals, and a Ka-band, multi-beam payload for communications.
  • Mynaric will supply 21 CONDOR Mk3 terminals to Raytheon for the program with the product deliveries expected in 2024.
  • Mynaric (NASDAQ: MYNA) (FRA: M0YN) is leading the industrial revolution of laser communications by producing optical communications terminals for air, space and mobile applications.

Quantum Technology Market Research Report 2023: Computing, Communications, Imaging, Security, Sensing, Modeling and Simulation Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 30, 2023
Technology, Other Technology, IBM, CONDOR, LIDAR, Defense, Internet of things, Communication, Infiltration, Microscopy, Edge computing, Defense Sciences Office, Microsoft, Research, Condor, Computer, Security, Data wrangling, Computing, DARPA, ICT, Dragon Computer & Communication, QCI, Nature, Risk, Commerce, U.S. Department of Defense Strategy for Operating in Cyberspace, Heron, Government, Quantum imaging, Hacking, Quantum technology, R, Transport, Aircraft, Quantum, Environment, Safety, Software, Microscope, Cryptocurrency, Blockchain

The "Quantum Technology Market by Computing, Communications, Imaging, Security, Sensing, Modeling and Simulation 2023 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Quantum Technology Market by Computing, Communications, Imaging, Security, Sensing, Modeling and Simulation 2023 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • It assesses companies/organizations focused on quantum technology including R&D efforts and potential gaming-changing quantum tech-enabled solutions.
  • The report provides an analysis of quantum technology investment, R&D, and prototyping by region and within each major country globally.
  • Much more than only computing, the quantum technology market provides a foundation for improving all digital communications, applications, content, and commerce.

Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific A

Retrieved on: 
Friday, May 26, 2023
Curium, CONDOR, Civil service commission, Prostate cancer, PSMA, European Medicines Agency, Committee for Medicinal Products for Human Use, Cancer, PET, Marketing, Committee, EMA, Nuclear medicine, Food and Drug Administration, Şakir, MD, Patient, Master of Science, Chief Medical Officer (Australia), INN, PCA, Phase, FDA, Recurrence, PSA, Food, European Commission, CHMP, Medical imaging, Piflufolastat F-18

Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented, “This positive CHMP opinion for PYLCLARI® is an important step forward in our goal of redefining the experience of cancer through our trusted legacy in nuclear medicine.

Key Points: 
  • Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented, “This positive CHMP opinion for PYLCLARI® is an important step forward in our goal of redefining the experience of cancer through our trusted legacy in nuclear medicine.
  • Upon its approval, PYLCLARI® will become available across Europe to help patients along their prostate cancer journey.
  • We are very excited to bring PYLCLARI® to the market and contribute to improving the set of diagnostic tools available to better diagnose and monitor prostate cancer.
  • The CHMP’s positive opinion on PYLCLARI® will be referred to the European Commission, which will deliver a final decision in approximately two months.

EQS-News: Mynaric optimizes management structure: Mustafa Veziroglu will become sole CEO with Bulent Altan set to join Supervisory Board

Retrieved on: 
Thursday, May 11, 2023
CONDOR, HAWK, Policy, Supervisory board, Lead, FRA, MK2, Supervision, SpaceX, Growth, Management, Mynaric

MUNICH, May 11, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective, and scalable laser communications products, today announced that the management and supervisory board jointly decided on a plan to further optimize the leadership structure of Mynaric.

Key Points: 
  • MUNICH, May 11, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective, and scalable laser communications products, today announced that the management and supervisory board jointly decided on a plan to further optimize the leadership structure of Mynaric.
  • Mustafa Veziroglu joined Mynaric’s management board in August 2022 and most recently served as Co-CEO of the company leading all operational product-related activities overseeing the entire product lifecycle from development through delivery.
  • His role as CEO will be to strengthen Mynaric’s focus on 2023 execution targets particularly with respect to production and positioning the company for long-term growth.
  • His role as part of the Supervisory Board will be to represent the company externally and to carry Mynaric’s vision of ubiquitous optical communications across the space industry.

EQS-News: Mynaric receives order from Loft Federal for CONDOR Mk3 optical communications terminals to support NExT – SDA’s Experimental Testbed

Retrieved on: 
Tuesday, May 2, 2023
Communication, CONDOR, SDA, Human, Northrop Grumman, SAR, Capella Space, Orbit, Telesat, Space Development Agency, Northrop, Grumman, FRA, Government, Sale, DARPA, MK2, NeXT, LOS, Surveying, Communications satellite, Mynaric, Longbow

LOS ANGELES, May 2, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced that it entered into a definitive agreement for the sale of CONDOR Mk3 terminals to Loft Federal, a subsidiary of Loft Orbital .

Key Points: 
  • LOS ANGELES, May 2, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced that it entered into a definitive agreement for the sale of CONDOR Mk3 terminals to Loft Federal, a subsidiary of Loft Orbital .
  • Loft Federal was selected to produce, deploy and operate NExT – the Space Development Agency's (SDA) Experimental Testbed and will use the terminals to support secure and reliable communications.
  • The order announced today was received in late 2022 and was already accounted for in the previously disclosed optical communications terminal backlog as of December 31, 2022.
  • “The CONDOR Mk3 terminal enables us to provide reliable performance on Longbow, our turnkey satellite platform,” said John Eterno, General Manager at Loft Federal.